Immunovia, Inc., the American subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), announced that it has received final approval to begin patient testing for the IMMray® PanCan-d test – the first blood test on the market dedicated to the early detection of pancreatic cancer.
Approximately 10-15% of all pancreatic cancer cases are attributed to a familial or hereditary link.
The IMMray® PanCan-d test is the first product developed from Immunovia’s proprietary immunoproteomics-based technology platform, IMMray®, that measures the immune system’s response to diseases in the blood. In a validation study presented in March, early-stage (stages I and II) pancreatic ductal adenocarcinomas were detected with 99% specificity and 89% sensitivity in familial/hereditary risk group cohorts.
The IMMray® PanCan-d test will be available exclusively from Immunovia, Inc., in Marlborough, MA, and is intended only for individuals who are at high-risk for developing familial or hereditary pancreatic cancer.
To learn more about the IMMray® PanCan-d test and familial/hereditary risk factors for pancreatic cancer, please visit: www.immunoviainc.com or contact: email@example.com